TIL
Instil Bio, Inc.
Biotechnology
Market Cap$54M
5Y Perf.-98.4%
Build Your Comparison
Side-by-side financial analysisTIL
ADCT
Try popular comparisons:
Stock Comparison
TIL vs ADCT
Revenue, margins, valuation, and 5-year total return — side by side.
ADCT
ADC Therapeutics S.A.
Biotechnology
Market Cap$134M
5Y Perf.-95.7%
TIL vs ADCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  TIL |  ADCT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $54M | $134M |
| Revenue (TTM) | $0.00 | $79M |
| Net Income (TTM) | $-47M | $-137M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -149.6% |
| Total Debt | $85M | $439M |
| Cash & Equiv. | $7M | $261M |
TIL vs ADCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TIL
ADCT
| Stock | Mar 21 | Jun 26 | Return |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 100 | 1.6 | -98.4% |
| ADC Therapeutics S.… (ADCT) | 100 | 4.3 | -95.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TIL vs ADCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TIL leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ADC Therapeutics S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇TIL emerged as the overall leader. Track its performance:
TIL
Instil Bio, Inc.
The Income Pick
TIL carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.55
- Lower volatility, beta 1.55, Low D/E 74.8%, current ratio 39.53x
- Beta 1.55, current ratio 39.53x
Best for: income & stability and sleep-well-at-night
ADCT
ADC Therapeutics S.A.
The Growth Play
ADCT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 14.9%, EPS growth 30.9%, 3Y rev CAGR -27.1%
- -96.5% 10Y total return vs TIL's -98.5%
- -71.4% vs TIL's -78.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  TIL | 37.2% revenue growth vs ADCT's 14.9% |
| Quality / Margins | TIL | -1.0% margin vs ADCT's -173.0% |
| Stability / Safety | TIL | Beta 1.55 vs ADCT's 1.84 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  ADCT | -71.4% vs TIL's -78.9% |
| Efficiency (ROA) | TIL | -22.4% ROA vs ADCT's -44.7% |
TIL vs ADCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TIL vs ADCT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTILLAGGINGADCT
ADCTADC Therapeutics S.A.
1leads
TILInstil Bio, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ADCTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TIL1/1
Valuation MetricsMultiples, price ratios, and targets
ADCT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TIL4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TIL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ADCT and TIL operate at a comparable scale, with $79M and $0 in trailing revenue.
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $79M |
| EBITDAEarnings before interest/tax | -$54M | -$117M |
| Net IncomeAfter-tax profit | -$47M | -$137M |
| Free Cash FlowCash after capex | -$34M | -$115M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -149.6% |
| Net MarginNet income ÷ Revenue | — | -173.0% |
| FCF MarginFCF ÷ Revenue | — | -144.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -9.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +85.6% | +41.7% |
TIL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ADCT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Market CapShares × price | $54M | $134M |
| Enterprise ValueMkt cap + debt − cash | $132M | $311M |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | -0.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.64x |
| Price / BookPrice ÷ Book value/share | 0.46x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ADCT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
TIL leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ADCT scores 4/9 vs TIL's 2/9, reflecting mixed financial health.
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| ROE (TTM)Return on equity | -39.8% | — |
| ROA (TTM)Return on assets | -22.4% | -44.7% |
| ROICReturn on invested capital | -18.0% | — |
| ROCEReturn on capital employed | -23.3% | -43.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.75x | — |
| Net DebtTotal debt minus cash | $79M | $178M |
| Cash & Equiv.Liquid assets | $7M | $261M |
| Total DebtShort + long-term debt | $85M | $439M |
| Interest CoverageEBIT ÷ Interest expense | -8.24x | -1.72x |
TIL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TIL and ADCT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADCT five years ago would be worth $453 today (with dividends reinvested), compared to $239 for TIL. Over the past 12 months, ADCT leads with a -71.4% total return vs TIL's -78.9%. The 3-year compound annual growth rate (CAGR) favors TIL at -11.1% vs ADCT's -25.4% — a key indicator of consistent wealth creation.
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| YTD ReturnYear-to-date | -29.7% | -70.2% |
| 1-Year ReturnPast 12 months | -78.9% | -71.4% |
| 3-Year ReturnCumulative with dividends | -29.8% | -58.5% |
| 5-Year ReturnCumulative with dividends | -97.6% | -95.5% |
| 10-Year ReturnCumulative with dividends | -98.5% | -96.5% |
| CAGR (3Y)Annualised 3-year return | -11.1% | -25.4% |
Evenly matched — TIL and ADCT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TIL and ADCT each lead in 1 of 2 comparable metrics.
Risk & Volatility
TIL is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than ADCT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.84x |
| 52-Week HighHighest price in past year | $38.50 | $4.97 |
| 52-Week LowLowest price in past year | $5.67 | $0.78 |
| % of 52W HighCurrent price vs 52-week peak | +20.6% | +21.1% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 14.9 |
| Avg Volume (50D)Average daily shares traded | 26K | 1.8M |
Evenly matched — TIL and ADCT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TILInstil Bio, Inc. | ADCTADC Therapeutics … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $3.50 |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TIL leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ADCT leads in 1 (Valuation Metrics). 2 tied.
Best OverallInstil Bio, Inc. (TIL)Leads 2 of 6 categories
Loading custom metrics...
TIL vs ADCT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TIL or ADCT a better buy right now?
Analysts rate ADC Therapeutics S.
A. (ADCT) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TIL or ADCT?
Over the past 5 years, ADC Therapeutics S.
A. (ADCT) delivered a total return of -95. 5%, compared to -97. 6% for Instil Bio, Inc. (TIL). Over 10 years, the gap is even starker: ADCT returned -96. 5% versus TIL's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TIL or ADCT?
By beta (market sensitivity over 5 years), Instil Bio, Inc.
(TIL) is the lower-risk stock at 1. 55β versus ADC Therapeutics S. A. 's 1. 84β — meaning ADCT is approximately 18% more volatile than TIL relative to the S&P 500.
04Which is growing faster — TIL or ADCT?
On earnings-per-share growth, the picture is similar: ADC Therapeutics S.
A. grew EPS 30. 9% year-over-year, compared to 6. 1% for Instil Bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TIL or ADCT?
Instil Bio, Inc.
(TIL) is the more profitable company, earning 0. 0% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TIL leads at 0. 0% versus -133. 2% for ADCT. At the gross margin level — before operating expenses — ADCT leads at 90. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TIL or ADCT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TIL or ADCT better for a retirement portfolio?
For long-horizon retirement investors, Instil Bio, Inc.
(TIL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TIL: -98. 5%, ADCT: -96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TIL and ADCT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.